FMP
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.3 USD
0.0412 (13.73%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
5.69B
6.77B
6.4B
6.16B
5.93B
6.02B
6.12B
6.21B
6.3B
6.4B
Revenue %
-
19.05
-5.58
-3.69
-3.67
1.53
1.53
1.53
1.53
Ebitda
534.95M
1B
971.51M
820.14M
693.17M
776.27M
788.14M
800.19M
812.43M
824.85M
Ebitda %
9.4
14.84
15.19
13.32
11.68
12.89
12.89
12.89
12.89
Ebit
415.59M
905.21M
864.76M
709.21M
575.1M
667.46M
677.67M
688.03M
698.55M
709.23M
Ebit %
7.3
13.36
13.52
11.51
9.69
11.08
11.08
11.08
11.08
Depreciation
119.36M
99.75M
106.75M
110.94M
118.07M
108.81M
110.47M
112.16M
113.88M
115.62M
Depreciation %
2.1
1.47
1.67
1.8
1.99
1.81
1.81
1.81
1.81
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
